Thomas Würdinger obtained his PhD in virology and gene therapy at Utrecht University, Utrecht, The Netherlands. After that he moved to Boston, USA to start his postdoc period as a research fellow at Massachusetts General Hospital and Harvard Medical School under the guidance of Prof. dr. X.O. Breakefield and Prof. dr. R. Weissleder. He has a position as professor at VU University Medical Center and Cancer Center Amsterdam, The Netherlands. He is co-founder of thromboDx BV and Exbiome BV.
I am currently the Charles Nowiszewski Professor of Cancer Biology at Boston Children’s Hospital and Harvard Medical School. I have expertise in the study of tumor metastasis and tumor resistance, with particular emphasis on prostate cancer. My laboratory has explored the molecular changes associated with acquisition of metastatic capability and taxane resistance. We have also developed novel markers that predict the acquisition of metastatic potential as well as drug resistance. My current work is focused on novel cancer therapeutics, including nanoparticle-mediated systemic delivery of siRNA and mRNA. I have participated on grant review panels for the NIH, American Cancer Society and Department of Defense and have chaired study sections on prostate and breast cancer as well as on tumor progression and metastasis. I have also chaired several scientific conferences, including two AACR Special Conferences on Prostate Cancer.